CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
骨肉瘤的肿瘤微环境：对免疫治疗的意义及新兴的治疗脆弱性（综述）
英文原题：Tumor microenvironment in bone sarcomas: Implications for immunotherapy and emerging therapeutic vulnerabilities (Review).
查看英文原题
Tumor microenvironment in bone sarcomas: Implications for immunotherapy and emerging therapeutic vulnerabilities (Review).
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
骨肉瘤尽管采用多模式治疗仍具致死性，主要因为矿化、免疫抑制的肿瘤微环境（TME）促进化疗和免疫耐药。整合骨肉瘤、Ewing肉瘤和软骨肉瘤的单细胞和空间组学，描绘出以M2巨噬细胞、耗竭T细胞和僵硬细胞外基质为主的亚型特异性TME原型。机制剖析揭示了可操作的脆弱性，即髓系重编程、细胞外基质调节以及代谢和表观遗传检查点，可通过骨选择性递送系统和生物标志物驱动的联合试验进行靶向，从而将治疗失败转化为持久缓解。因此，本综述的目的是综合最新的单细胞、空间和功能数据，以绘制骨肉瘤TME异质性图谱，剖析耐药机制，并提出可转化为治疗的综合、生物标志物指导的治疗策略。
展开英文摘要原文
<p>Bone sarcomas remain lethal despite multimodal therapy, primarily because the mineralized, immunosuppressive tumor microenvironment (TME) promotes chemo‑ and immune‑resistance. Integrating single‑cell and spatial omics across osteosarcoma, Ewing sarcoma and chondrosarcoma delineates subtype‑specific TME archetypes dominated by M2 macrophages, exhausted T cells and a stiff extracellular matrix.
Mechanistic dissection reveals tractable vulnerabilities, myeloid reprogramming, extracellular matrix modulation and metabolic and epigenetic checkpoints, that can be targeted with bone‑selective delivery systems and biomarker‑driven combination trials to convert therapeutic failure into durable remission.
Therefore, the aim of the present review is to synthesize the latest single‑cell, spatial and functional data to map bone‑sarcoma TME heterogeneity, dissect resistance mechanisms and propose integrated, biomarker‑guided therapeutic strategies that can be translated into treatments. </p>.
论文信息
- 作者
- Li W、Lv L、Jin Y、Yuan X
- 单位
- Department of Orthopedic Surgery, The Third Affiliated Hospital of Gansu University of Chinese Medicine, Baiyin, Gansu 730900, P.R. China.China
- 文献类型
- 综述
- 期刊
- Oncology reports2026 Mar
- 原文标识
- PubMed 41543186 · DOI 10.3892/or.2026.9050
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →